Amishi Yogesh Shah

May 21, 2024 | europeanurology.com | Matthew Taylor |James J. Hsieh |Regina Gironés Sarrió |Christopher Di Simone |Chung-Han Lee |Amishi Yogesh Shah | +10 more

1 Taylor M.H. Lee C.H. Makker V. et al. Phase Ib/II trial of lenvatinib plus pembrolizumab in patients with advanced renal cell carcinoma, endometrial cancer, and other selected advanced solid tumors. J Clin Oncol. 38: 1154-1163 ]. In the RCC cohort, LEN + PEM exhibited antitumor activity irrespective of prior treatment, and notably among patients who had received prior immune checkpoint inhibitors (ICIs) [ 2 Lee C.H. Shah A.Y. Rasco D. et al.